戸井 雅和 先生のプロフィール

戸井 雅和 先生

とい まさかず

戸井 雅和 先生

京都大学大学院医学研究科外科学講座乳腺外科学 教授

戸井 雅和 先生のストーリー記事を読む

専門分野

乳がん診療

紹介

1982年に広島大学医学部を卒業。1990年より2年間イギリス・オックスフォード大学附属John-Radcliffe Hospital臨床腫瘍学部門に留学、1992年には東京都駒込病院外科へ。2007年より現職。高い外科的技術力と豊富な知識、広い視野を併せ持つ、乳がん治療のスペシャリストとして第一線で活躍している。

略歴

1982年 広島大学医学部卒業
1990年 英国Oxford 大学分子医学研究所・Oxford大学附属John-Radcliffe Hospital臨床腫瘍学部門に留学
1992年 東京都立駒込病院外科
2007年 京都大学大学院医学研究科 外科学講座乳腺外科学 教授

所属学会・資格・役職など

【所属学会】
日本外科学会、日本癌治療学会、日本癌学会、日本消化器外科学会、日本乳癌学会、日本臨床外科学会、日本乳癌検診学会、日本癌分子標的治療学会、日本臨床腫瘍学会他
American Association for Cancer Research, American Society of Clinical Oncology
Society of Surgical Oncology, European Association for Cancer Research

【認定資格】
日本外科学会専門医、日本乳癌学会専門医、日本外科学会指導医、日本臨床腫瘍学会暫定指導医

受賞・著書・論文など

【受賞】
日本乳癌学会奨励賞(1995)、
日本乳癌学会久野賞(1998)

【著書】
『乳がんレビュー(2009)』 戸井雅和編著 (2009年メディカルレビュー社)
『みんなに役立つ乳癌の基礎と臨床』戸井雅和編 (2009年 医薬ジャーナル社)
Toi, M., Winer, E., Benson, J, Klimberg, S. (Eds.) Personalized Treatment of Breast Cancer, Springer 2016
Toi M and Winer EP. Local and systemic management of primary breast cancers. Kyoto University press, 2010.
など

【論文】
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Spraggs CF, et al.
Pharmacogenom

【受賞】
日本乳癌学会奨励賞(1995)、
日本乳癌学会久野賞(1998)

【著書】
『乳がんレビュー(2009)』 戸井雅和編著 (2009年メディカルレビュー社)
『みんなに役立つ乳癌の基礎と臨床』戸井雅和編 (2009年 医薬ジャーナル社)
Toi, M., Winer, E., Benson, J, Klimberg, S. (Eds.) Personalized Treatment of Breast Cancer, Springer 2016
Toi M and Winer EP. Local and systemic management of primary breast cancers. Kyoto University press, 2010.
など

【論文】
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Spraggs CF, et al.
Pharmacogenomics J. 2017 Aug 8. doi: 10.1038/tpj.2017.39. [Epub ahead of print]

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Tanaka Y, et al.
Sci Rep. 2017 Jul 20;7(1):5987. doi: 10.1038/s41598-017-05553-0.

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
Ohgami M, et al..
Ann Oncol. 2017 Jun 26. doi: 10.1093/annonc/mdx328.

Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
Nishimatsu K, et al.
Eur J Radiol. 2017 May;90:138-145. doi: 10.1016/j.ejrad.2017.02.046.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW Jr, et al.
J Clin Oncol. 2017 Jun 3:JCO2017737585. doi: 10.1200/JCO.2017.73.7585.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, et al.
N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.

Ultrafast dynamic contrast-enhanced mri of the breast using compressed sensing: breast cancer diagnosis based on separate visualization of breast arteries and veins.
Onishi N, et al.
J Magn Reson Imaging. 2017 May 28. doi: 10.1002/jmri.25747.

Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity.
Kawaguchi K, et al.
Cancer Immunol Immunother. 2017 Apr 21. doi: 10.1007/s00262-017-2002-2.

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Toi M, et al.
Breast Cancer Res. 2017 Apr 11;19(1):47. doi: 10.1186/s13058-017-0839-0.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Sonnenblick A, et al.
J Clin Oncol. 2017 May 1;35(13):1421-1429. doi: 10.1200/JCO.2016.69.7722. E

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.
Chow LW, et al.
Asia Pac J Clin Oncol. 2017 Mar 28. doi: 10.1111/ajco.12682.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Kawaguchi H, et al.
Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x.

Diagnostic performance of a novel dedicated breast PET scanner with C-shaped ring detectors.
Nakamoto R, et al.
Nucl Med Commun. 2017 May;38(5):388-395. doi: 10.1097/MNM.0000000000000661.

Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array.
Toi M, et al.
Sci Rep. 2017 Feb 7;7:41970. doi: 10.1038/srep41970.

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Perez EA, et al.
J Clin Oncol. 2017 Jan 10;35(2):141-148.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Bell R, et al.
Ann Oncol. 2017 Apr 1;28(4):754-760. doi: 10.1093/annonc/mdw665.

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N, et al.
Breast Cancer Res. 2016 Dec 19;18(1):129.

Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images.
Asao Y, et al.
J Biomed Opt. 2016 Nov 1;21(11):116009. doi: 10.1117/1.JBO.21.11.116009.

Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis.
Sugie T, et al.
Int J Clin Oncol. 2017 Feb;22(1):11-17. doi: 10.1007/s10147-016-1064-z.

The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells.
Itou J, et al.
Biochim Biophys Acta. 2017 Jan;1864(1):76-88. doi: 10.1016/j.bbamcr.2016.10.012.

Treatment of low-risk ductal carcinoma in situ: is nothing better than something?
Benson JR, Jatoi I, Toi M.
Lancet Oncol. 2016 Oct;17(10):e442-e451. doi: 10.1016/S1470-2045(16)30367-9.

De-escalation of axillary surgery in early breast cancer.
Jatoi I, Benson JR, Toi M.
Lancet Oncol. 2016 Oct;17(10):e430-e441. doi: 10.1016/S1470-2045(16)30311-4.

Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan.
Ikeda T, et al.
Breast Cancer. 2017 Mar;24(2):341-344. doi: 10.1007/s12282-016-0720-5.

Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation.
Hirata K, et al.
J Radiat Res. 2017 Jan;58(1):79-85. doi: 10.1093/jrr/rrw071. Epub 2016 Jul 15.

Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery.
Lee ES, et al.
Eur J Surg Oncol. 2016 Aug;42(8):1169-75. doi: 10.1016/j.ejso.2016.04.058.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F, et al.
J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161.

Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.
Shi G, et al.
Oncotarget. 2016 Dec 13;7(50):82158-82169. doi: 10.18632/oncotarget.8620.

A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells.
Li W, et al.
Exp Cell Res. 2016 May 1;343(2):177-189. doi: 10.1016/j.yexcr.2016.03.023.

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
Ueno T, et al.
BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9.

Data of a fluorescent imaging-based analysis of anti-cancer drug effects on three-dimensional cultures of breast cancer cells.
Itou J, et al.
Data Brief. 2015 Oct 8;5:429-33. doi: 10.1016/j.dib.2015.09.037. eCollection 2015 Dec.

Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
Kawaguchi K, et al.
Breast Cancer. 2017 Jan;24(1):111-120. doi: 10.1007/s12282-016-0682-7.

Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.
Hayakawa Y, et al.
Cancer Sci. 2016 Feb;107(2):189-202. doi: 10.1111/cas.12857.

Statistical controversies in clinical research: statistical significance-too much of a good thing ….
Buyse M, et al.
Ann Oncol. 2016 May;27(5):760-2. doi: 10.1093/annonc/mdw047.

A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result?
Onishi N, et al.
Breast Cancer. 2017 Jan;24(1):69-78. doi: 10.1007/s12282-016-0668-5.

Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls.
Kawaguchi-Sakita N, et al.
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1140-5. doi: 10.1016/j.bbrc.2015.12.114.

For choosing axillary treatment, and adjuvant hormonal treatment.
Toi M, et al.
Breast Cancer. 2016 Mar;23(2):167-9. doi: 10.1007/s12282-015-0662-3.

続きを見る

戸井 雅和先生 の所属する医療機関

京都大学医学部附属病院

TEL: 075-751-3111

京都大学医学部附属病院

京都府京都市左京区聖護院川原町54

京阪電気鉄道鴨東線「神宮丸太町駅」 徒歩10分

JR東海道本線「京都駅」 近畿日本鉄道京都線、京都市営地下鉄烏丸線も乗り入れあり 八条口より直通路線バス「京大病院ライナー」利用可(有料) バス30分

- - -

受付時間: 8:15~11:00 原則紹介制、一部診療科予約制 診療9:00~開始 科により異なる 創立記念日(6/18)休診 臨時休診あり

診療科目: 内科 血液内科 リウマチ科 外科 精神科 神経内科 脳神経外科 呼吸器外科 消化器外科 腎臓内科 心臓血管外科 小児科 小児外科 整形外科 形成外科 皮膚科 泌尿器科 産婦人科 眼科 耳鼻咽喉科 リハビリテーション科 放射線科 歯科口腔外科 麻酔科 乳腺外科

戸井 雅和 先生 の記事